Niagen Bioscience (NAGE) Payables (2011 - 2026)

Niagen Bioscience (NAGE) has reported Payables for 14 consecutive years, with $13.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 24.88% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $13.3 million (up 24.88% YoY), while the FY2025 annual figure was $10.8 million, up 26.62% from the prior year.
• Payables improved to $13.3 million in Q1 2026 per NAGE's latest filing, from $10.8 million in the prior quarter.
• Across five years, Payables topped out at $13.7 million in Q2 2025 and bottomed at $6.9 million in Q3 2024.
• Historically, Payables has averaged $10.0 million across 5 years, with a median of $9.8 million in 2022.
• Annual changes were most pronounced in 2024 — Payables fell 24.95% — and 2025, when it surged 84.59%.
• Niagen Bioscience's Payables stood at $9.7 million in 2022, then climbed by 5.71% to $10.2 million in 2023, then fell by 16.67% to $8.5 million in 2024, then increased by 26.62% to $10.8 million in 2025, then rose by 22.98% to $13.3 million in 2026.
• Business Quant data shows NAGE's Payables at $13.3 million in Q1 2026, $10.8 million in Q4 2025, and $12.7 million in Q3 2025.